$664 Thousand is the total value of COMMODORE CAPITAL LP's 35 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | NUVALENT INC | $27,208 | – | 913,621 | +100.0% | 4.10% | – | |
| IMVT | New | IMMUNOVANT INC | $20,421 | – | 1,150,505 | +100.0% | 3.08% | – |
| New | ARCELLX INC | $18,323 | – | 591,437 | +100.0% | 2.76% | – | |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $13,987 | – | 127,156 | +100.0% | 2.11% | – |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $13,290 | – | 598,385 | +100.0% | 2.00% | – |
| RNA | New | AVIDITY BIOSCIENCES INC | $13,108 | – | 590,705 | +100.0% | 1.98% | – |
| IMRA | New | IMARA INC | $10,204 | – | 2,494,794 | +100.0% | 1.54% | – |
| ETNB | New | 89BIO INC | $9,652 | – | 758,244 | +100.0% | 1.46% | – |
| CABA | New | CABALETTA BIO INC | $9,346 | – | 1,010,359 | +100.0% | 1.41% | – |
| PCVX | New | VAXCYTE INC | $8,318 | – | 173,481 | +100.0% | 1.25% | – |
| DBVT | New | DBV TECHNOLOGIES S Asponsored adr | $142 | – | 92,687 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.